Alliqua BioMedical, Inc. (ADYX) [Rocket]

Overview

Alliqua BioMedical, Inc. (ADYX)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
03/20/2020	15-12B	Form 15-12B - Securities registration termination [Section 12(b)]:
03/20/2020	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/20/2020	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/20/2020	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/20/2020	S-8 POS	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
03/20/2020	RW	Form RW - Registration Withdrawal Request:
12/17/2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14	Dec-31-13	Dec-31-12	Dec-31-11
Revenues	2.2	2.0	16.3	12.2	4.8	1.8	1.2	1.8
Revenue growth	9.8%	-87.6%	33.8%	154.4%	166.2%	46.3%	-32.9%	38.9%
Cost of goods sold	1.7	1.8	6.1	5.2	3.3	2.0	1.8	1.9
Gross profit	0.5	0.2	10.2	7.0	1.5	-0.2	-0.6	-0.1
Gross margin	22.4%	8.8%	62.9%	57.1%	31.7%	-13.9%	-49.5%	-4.7%
Selling, general and administrative	5.8	5.3	35.3	34.3	26.2	11.7	4.1	3.9
Research and development			0.9	0.7		0.1	0.2	0.5
EBITA	-5.3	-4.8	-17.4	-27.1	-25.2	-11.7	-4.5	-13.5
EBITA margin	-239.0%	-235.8%	-107.0%	-222.6%	-526.9%	-648.7%	-370.0%	-736.7%
Amortization of intangibles			3.5	2.4	0.2	0.4	0.4	0.4
EBIT	-5.3	-4.8	-20.9	-29.5	-25.4	-12.0	-4.9	-13.8
EBIT margin	-239.0%	-235.8%	-128.4%	-242.3%	-531.1%	-669.3%	-398.5%	-755.8%
Pre-tax income	-7.0	-4.2	-33.8	-28.9	-25.4	-22.0	-4.9	-13.8
Income taxes	0.0	0.0	-0.7	-1.7	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	2.1%	5.9%
Earnings from continuing ops	-7.0	-4.2	-33.0	-27.2	-25.4	-22.4	-4.9	-13.9
Earnings from discontinued ops	5.5	1.7	3.3
Net income	-8.4	-25.7	-28.2	-26.0	-25.4	-22.4	-4.9	-13.9
Net margin	-379.8%	-1273.3%	-173.3%	-213.7%	-531.6%	-1248.2%	-399.2%	-756.1%

Diluted EPS	($1.42)	($0.99)	($11.81)	($1.18)	($1.74)	($3.14)	($0.91)	($0.07)
Shares outstanding (diluted)	4.9	4.3	2.8	23.1	14.6	7.1	5.4	207.1

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.